HOME >> BIOLOGY >> NEWS
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of 64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses. The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better (P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients wi
'"/>

Contact: Prof Per Hall
per.hall@ki.se
46-73-625-0342
Karolinska Institutet
2-Oct-2005


Page: 1 2

Related biology news :

1. The Center of Nutrigenomics of the TU Munich licences Genomatix Microarray Analysis Pipeline
2. German Microarray Excellence Center integrates Genomatix Chip Analysis Pipeline
3. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible status
4. Microarrays as phenotype
5. AFCYBER holds science and technology symposium
6. New technology reveals seal behavior
7. Nanotechnology helps scientists make bendy sensors for hydrogen vehicles
8. FDA Nanotechnology Task Force takes positive step forward
9. Liverpool amongst first in UK to install unique DNA sequencing technology
10. EPA foregoes opportunity to improve nanotechnology oversight
11. The Cancer Genome Atlas awards funds for technology development

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Microarray technology for tailoring breast cancer therapy

(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
(Date:5/4/2015)... Tenn. , May 4, 2015   ... developed a significantly better computer tool for finding ... many cancers but were difficult to identify with ... scientific journal Nature Methods . ... for Copy Number Segmentation by Regression Tree in ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - Fluorinov ... to announce the appointment of Dr. Roger J ... experience guiding biotech companies in matters including corporate ... leadership team and adds significant regulatory expertise as ... Dr. Garceau brings 30 years of pharmaceutical development ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin ... 10 to 100x better detail than the industry standard. ... existing light microscopy methods, it needed another medium to ... the frame of reference because it represents the highest ... from the earliest discovery days of Ultralight Histology was ...
(Date:5/4/2015)... , May 4, 2015   Tocagen Inc. ... interim data from Tocagen,s ongoing investigational studies were ... of the American Association of Neurological Surgeons (AANS)/Congress ... May 1-2, 2015, in Washington, D.C. ... held a meeting with FDA and continues to ...
Breaking Biology Technology:Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5
Cached News: